Physician profile
John Ackert
NPI 1053335810
$3,882.45
in general payments reported to CMS, 2019-2025
24 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,679 · 2020: $541 · 2022: $359 · 2023: $99.49 · 2024: $101 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $975.44 | 2019-2022 | |
| Abbvie INC. | $697.69 | 2019-2025 | |
| Janssen Biotech, INC. | $408.81 | 2019-2024 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $291.41 | 2019-2024 | Entyvio |
| Qol Medical, LLC | $282.73 | 2019-2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $234.93 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $180.67 | 2019-2023 | Dificid |
| Celgene Corporation | $165.25 | 2022-2023 | Zeposia |
| Pfizer INC. | $117.34 | 2019 | |
| Ironwood Pharmaceuticals, INC | $106.54 | 2019-2020 | |
| Allergan, INC. | $86.86 | 2019 | |
| Lilly USA, LLC | $50.33 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $43.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $30.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.40 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $24.61 | 2024 | Voquezna |
| Eisai INC. | $24.31 | 2019 | |
| Redhill Biopharma INC. | $23.71 | 2020 | |
| Daiichi Sankyo INC. | $22.86 | 2019 | |
| Napo Pharmaceuticals INC | $21.65 | 2019 | |
| Amarin Pharma, INC. | $19.32 | 2019 | |
| Braintree Laboratories, INC. | $17.00 | 2019 | |
| Phadia US INC. | $16.97 | 2019 | |
| Ucb, INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ackert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.